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INTRODUCTION
Cancer is a major cause of morbidity
and mortality worldwide and its burden is
globally increasing. Although endocrine
cancers are relatively uncommon, they may
be one the most important and potentially
treatable cancers. In fact, thyroid cancer is
the most prevalent form of endocrine cancer,
accounting for 1% of all new cancers (0.5%
of cancers in men and 1.5% of cancers in
women).1-3 The worldwide incidence rate of
thyroid cancer (TC) is generally lower than
3 per 100,000 in men and 5 per 100,000 in
women.4-8 TC is indeed one of 10 (the
eighth) leading common cancers among
women in the world.9
TC has four main histological types;
papillary (PTC) accounts for 80%, follicular
(FTC) 10-15%, medullary (MTC) 5-7%, and
anaplastic (ATC) 1-2% of all thyroid cancer
types. In addition, PTC is the most prevalent
type, and it is three times more common in
women than men.5,8,10 Five-year survival
rate for PTC is higher than 90%, for FTC
higher than 90%, for MTC 30-80%, and for
ATC 1-17%.11 TC is mostly diagnosed
among people aged from 45-54 years with
median age of diagnosis of 50 years. The
percentage of mortality from TC is highest
among people aged 75-84 with median age
of 73 years at death.12
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ABSTRACT
Background and aims: Thyroid cancer is the most common endocrine malignant and
papillary cancer and three times more prevalent in women than men. The aim of this
study was to evaluate the incidence rate and trend of thyroid cancer in Iranian population.
Methods: National incidence was rated by Iran National Cancer Registry data derived
from Iran’s annual national cancer registration reported from 2003 to 2009. The crude
rate and age standardized rate were used to express the incidence of thyroid cancer.
Results: The results indicated that, the incidence of thyroid cancer increased from 2003
to 2009. The age standardized rate for women and men increased from 2.02 and 0.82 to
4.2 and 1.36 per 100,000, respectively.
Conclusion: This study indicated remarkable increasing trends in thyroid cancer
incidence. So, attention to high risk groups and public programs is necessary to reduce
the incidence of this cancer in future.
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In a survey conducted by the Iranian
Cancer Institute, 1.8% of all cancers and
76.1% of all endocrine cancers constituted
by the neoplasm of thyroid gland; for
example, in a study in Iran, mean age of
Iranian patients was 42.8 years (95% CI:
41.9-43.7) with markedly older male
patients.8,13 Also, the female to male ratio
was about 1.8, while this ratio was 1.3 for
anaplastic carcinoma due to the higher
proportion of the affected men.8,14 The aim
of this study was to determine the trends of
TC incidence in Iranian general population
from 2003 to 2009.
METHODS
The data were extracted from Iran
National Cancer Registry data derived from
Iran’s annual national cancer registration
reported from 2003 to 2009 (Islamic
Republic of Iran Ministry of Health and
Medical Education, Center for Disease
Control and Prevention, Noncommunicable
Deputy Cancer Office, 2009).15 The Iran
Ministry of Health and Medical Education
registers all the new cancer cases, according
to pathology reports, in all provinces and the
data are publicized after revision.
Age standardized rate (ASR) and crude
death rate (CDR) of TC (ICD-9: 193) for
men and women from 2003 to 2009 were
expressed per 100,000 as the annual
incidence, overall and for all provinces.
Then, the trend of ASR, CDR, and five most
common morphologies of TC in Iran were
drawn.
RESULTS
All incidence records of TC from 2003
to 2009 were included in the analysis. The
ASR of TC dramatically increased during
these years from 1.42 to 2.78 per 100,000
for both men and women. In women, this
rate varied from 2.02 to 4.2 per 100,000 and
in men from 0.82 to 1.36 per 100,000. The
CDR of TC increased from 1.24 to 2.57 per
100,000 for both men and women. In
women, it varied from 1.75 to 3.96 per
100,000 and in men from 0.74 to 1.17 per
100,000 (Table 1 and Figure 1). The highest
ASR of TC was derived in Isfahan province
for all years under study. For some
provinces, no data reported (Table 2).
Table 1: Crude rate (CR) and age
standardized rate (ASR; per 100,000) for
thyroid cancer incidence in Iran
Years ASR CR
females males females Male
s
2003 2.02 0.82 1.75 0.74
2004 2.8 1.06 2.42 0.9
2005 3.47 1.16 2.93 0.98
2006 3.76 1.3 3.32 1.12
2007 3.4 1.11 2.98 0.95
2008 4.47 1.51 3.85 1.31
2009 4.2 1.36 3.96 1.17
Figure 1: Age standardized rate (ASR) and
crude rate (CR) of thyroid cancer for female
and male in Iran (2003-2009)
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Table 2: The age standardized rate (ASR) for thyroid cancer incidence (per 100,000) from all provinces in Iran
Province 2004 2005 2006 2007 2008
ASR
F
ASR
M
ASR
total
ASR
F
ASR
M
ASR
total
ASR
F
ASR
M
ASR
total
ASR
F
ASR
M
ASR
total
ASR
F
ASR
M
ASR
total
East Azarbaijan 2.89 1.24 2.065 1.14 0.4 0.77 0.35 0.48 0.415 4.46 1.67 3.065 7.09 2.44 4.765
West Azarbaijan 1.47 0.43 0.95 1.5 0.45 0.975 3.21 0.84 2.025 2.82 1.34 2.08 2.74 1.2 1.97
Ardebil 4.25 0.95 2.6 0.27 0.19 0.23 3.76 1.3 2.53 2.49 0.2 1.345 3.03 1.8 2.415
Esfahan 4.01 2.09 3.05 5.48 1.3 3.39 5.85 1.54 3.695 5.62 1.48 3.55 8.17 2 5.085
Ilam 3.28 2.2 2.74 1.03 2.2 0.84 1.52 0.24 0.89 0.565 2.38 0.66 1.52
Bushehr 1.36 0.67 1.015 2.18 2.02 2.1 2.21 0.83 1.52 3.36 0.63 1.995 2.93 0.62 1.775
Tehran 2.76 0.64 1.7 3.57 1.14 2.355 3.59 1.22 2.405 2.8 0.93 1.865 5.29 1.74 3.515
Chaharmahalbakhtiari 2.93 2.89 2.91 8.19 1.8 4.995 7.99 1.02 4.505 5.12 0.78 2.95 5.52 2.53 4.025
South Khorasan 0.86 0.32 0.59 0.37 0.43 0.4 0.76 2.08 1.52 1.8
KhorasanRazavi 1.98 1.24 1.61 1.9 0.78 1.34 3.66 1.19 2.425 2.43 0.86 1.645 3.01 0.99 2
North Khorasan 1.97 0.74 1.355 0.69 0.33 0.51 1.45 0.56 1.005 2.11 2.56 2.335
Khozestan 2.47 1.06 1.765 2.08 0.47 1.275 2.84 0.56 1.7 1.99 0.64 1.315 4.1 0.87 2.485
Zanjan 1.85 0.67 1.26 2.71 0.17 1.44 2.23 0.9 1.565 1.78 0.56 1.17 2.11 0.43 1.27
Semnan 2.34 1.53 1.935 1.7 1.13 1.415 3.9 1.15 2.525 1.2 0.97 1.085 1.68 0.64 1.16
Sistanbalochestan 1.25 0.32 0.785 0.79 1.03 0.91 1.26 0.57 0.915 0.88 0.64 0.76 1.53 0.72 1.125
Fars 2.2 0.82 1.51 3.54 1.3 2.42 3.34 1.36 2.35 5.61 1.59 3.6 6.25 1.87 4.06
Ghazvin 4.04 0.62 2.33 3.83 1 2.415 3.9 0.97 2.435 3.51 1.05 2.28 2.92 1.56 2.24
Qom 1.63 1.28 1.455 2.37 0.35 1.36 2.74 0.93 1.835 2.9 0.47 1.685 1.18 0.48 0.83
Kordestan 1.61 0.33 0.97 1.18 0.36 0.77 2.16 0.59 1.375 2.16 1.06 1.61 2.71 1.22 1.965
Kerman 2.89 2.16 2.525 3.28 0.37 1.825 3.61 1.15 2.38 3.77 1.47 2.62 4.61 1.1 2.855
Kermanshah 1.42 1.05 1.235 2.83 1.36 2.095 3.44 0.43 1.935 3.05 1.46 2.255 4.26 1.46 2.86
Kohgiloyeboyerahmad 4.76 1.24 3 1.39 1.25 1.32 1.86 1.61 1.735 5.85 0.36 3.105 4.39 0.93 2.66
Golestan 2.65 0.75 1.7 1.78 0.64 1.21 3.42 1.36 2.39 2.26 0.51 1.385 2.93 1.41 2.17
Gilan 1.99 0.54 1.265 2.29 0.67 1.48 2.49 1.2 1.845 1.72 1.33 1.525 5.77 1.61 3.69
Lorestan 1.91 0.35 1.13 1.63 0.28 0.955 2.32 1.31 1.815 2.28 0.81 1.545 2.82 1.95 2.385
Mazandaran 2.8 0.78 1.79 3.28 1.33 2.305 4.3 0.85 2.575 3.51 0.86 2.185 3.9 1.69 2.795
Markazi 1.46 0.66 1.06 3.42 0.36 1.89 3.78 1.28 2.53 2.5 0.63 1.565
Hormozgan 2.04 0.19 1.115 1.66 0.55 1.105 1.47 0.45 0.96 1.58 0.13 0.855
Hamedan 1.95 0.89 1.42 3.02 0.6 1.81 3.2 1.47 2.335 1.92 0.62 1.27
Yazd 5.01 0.22 2.615 4.26 0.99 2.625 3.62 2.38 3 4.63 0.9 2.765
M: Male, F: Female
The trend of five most common
morphologies of TC in Iran from 2003 to
2008 was also assessed; the papillary
adenocarcinoma was the most common
thyroid tumor followed by papillary
carcinoma follicular variant, follicular
adenocarcinoma, medullary carcinoma, and
anaplastic carcinoma (Table 3).
Table 3: The number of cases according to five most common morphologies of thyroid cancer in Iran
Years a b c d eF M Both F M Both F M Both F M Both F M Both
2003 414 180 594 50 18 68 47 12 59 27 23 50 9 8 17
2004 568 204 772 78 22 100 44 21 65 25 26 51 16 7 23
2005 695 260 956 78 19 97 64 16 80 48 30 78 16 9 25
2006 824 270 1094 91 25 116 55 14 69 43 29 72 18 10 28
2007 757 233 990 112 32 144 13 4 17 38 27 65 11 14 25
2008 960 322 1282 90 21 111 66 11 77 48 43 91 14 9 23
a) Papillary Adenocarcinoma, NOS; b) Papillary Carcinoma, Follicular Variant; c) Follicular Adenocarcinoma;
d) Medullary Carcinoma, NOS; e) Carcinoma, Anaplastic, NOS; M: Male, F: Female.
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Estimated TC incidence, mortality,
and 5-year prevalence, based on
GLOBOCAN2012, for the whole world,
more developed regions, less developed
regions, ASIA, Islamic Republic of Iran,
WHO Americas region (PAHO), and
WHO Europe region (EURO), are
presented in Table 4.
Table 4: Estimated thyroid cancer incidence, mortality, and 5-year prevalence according to
GLOBOCAN 2012
Varieties Gender Incidence Mortality 5-year prevalence
Number % *ASR (W) Number % *ASR (W) Number % Prop.
World Men 68179 0.9 1.9 12627 0.3 0.3 271270 1.8 10.4
Women 229923 3.5 6.1 27142 0.8 0.6 934805 5.6 36.0
Both sexes 298102 2.1 4.0 39769 0.5 0.5 1206075 3.7 23.2
More Developed
Regions
Men 29672 0.9 3.6 3651 0.2 0.3 121600 1.4 24.3
Women 93104 3.3 11.1 6740 0.5 0.4 392196 4.7 72.7
Both sexes 122776 2.0 7.4 10391 0.4 0.4 513796 3.0 49.4
Less Developed
Regions
Men 38507 0.9 1.4 8976 0.3 0.4 149670 2.2 7.1
Women 136819 3.6 4.7 20402 0.9 0.7 542609 6.1 26.4
Both sexes 175326 2.2 3.0 29378 0.6 0.6 692279 4.4 16.7
ASIA Men 32858 0.9 1.5 7127 0.3 0.3 129384 2.1 0.8
Women 111621 3.6 5.0 15286 0.8 0.7 451739 6.3 28.9
Both sexes 144479 2.1 3.2 22413 0.5 0.5 581123 4.4 18.3
Islamic Republic
of Iran
Men 513 1.1 1.4 181 0.6 0.5 1885 2.4 6.4
Women 1512 3.8 4.0 429 1.8 1.4 5772 6.4 20.0
Both sexes 2025 2.4 2.7 610 1.1 0.9 7657 4.5 13.1
WHO Americas
Region (PAHO)
Men 19401 1.3 3.7 1879 0.3 0.3 81176 2.1 23.0
Women 66065 4.6 12.1 3372 0.5 0.5 280246 6.8 76.0
Both sexes 85466 3.0 8.0 5251 0.4 0.4 361422 4.5 50.1
WHO Europe
Region (EURO)
Men 14036 0.7 2.5 2379 0.2 0.3 54900 1.1 15.4
Women 48775 2.8 8.1 5088 0.6 0.5 192534 3.9 49.5
Both sexes 62811 1.7 5.4 7467 0.4 0.4 247434 2.5 33.2
*ASR: age standardized rate
DISCUSSION
This study, indicated a remarkable
increasing trend in TC incidence, based on
the national registry data from 2003 to 2009.
This trend was different for men and
women. Enhanced detection could
contribute to the increased TC incidence in
the past decades, but cannot fully explain the
increase, suggesting that maybe a true
increase exists.16 In addition, when the main
reason is the increasing detection, the
improvement in small and early-stage
tumors should be accompanied by a
progressive decline of larger and more
advanced tumors. The TC increases, while
most prominent for small tumors and across
all tumor sizes and stages, suggesting that
increasing of detection is not the only
reason.17-19 The remarkable increase in
incidence of TC in advanced stages, usually
clinically apparent, is too difficult to be
explained by increased detection. Moreover,
the TC increase has been almost exclusively
observed for papillary tumors, while
improved detection must affect all
histotypes.17 Finally, when increasing of
detection is the only reason, it is expected
that the cancer increase to be observed in all
age and gender categories. Indeed, the age-
adjusted incidence rates of TC have
increased in women more than in men
(158% vs. 106%) with a clear birth cohort
pattern, possibly reflecting changes in risk
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factors and the birth cohort contribution
which suggest that the increasing of
detection is not the only reason of the
increased incidence of TC.17, 20
Furthermore, by the report of
GLOBOCAN 2012, annually 298102 new
cases of TC occurred around the world.9 In the
United States, TC is the ninth leading cancer
and it is estimated that new cases would
register 62,980 in 2014. Five-year survival was
about 97.8% in 2004-2010. Using statistical
models of analysis, rates of new TC cases have
been rising on average by 5.5% per year over
the last 10 years.12 In the United Kingdom
2,727 people were diagnosed with TC in 2011.
Around 75.0% of adult TC patients (74.2% of
men and 78.9% of women) in England and
Wales survived five years or longer during
1996-1999.21 TC represents 2.1% of all new
cancer cases in the world, 3.0% in WHO
Americas region, 2.4% in Iran, 2.2% in less
developed regions, 2.1% in Asia, 2% in more
developed regions, and 1.7% in WHO Europe
region.9
Study of potential etiologic and risk
factors of TC showed that radiation exposure,
genetic factors, pre-existing thyroid disease,
hormonal and reproductive factors (as the
cancer is more frequent in women),  and
dietary factors (specially iodine) could play the
main roles in pathogenesis of TC.22,23
The limitation of this study was the
incomplete data which were collected from
all provinces before 2004 and no published
information for provinces after 2008. In
addition, from 2003 to 2009, the coverage of
registered new cancer cases was increasing.
So, for the early years under the study, the
collected data could suffer from
underestimation.
CONCLUSION
This study indicated an increasing
incidence of TC in Iranian population. Since
many cases of TC could be treated
successfully, it is expected to diagnose TC at
early stages. Therefore, the development of
a guideline can be helpful to diagnose TC at
early stages. Moreover, attention to high risk
groups and setting awareness programs
should be focused to reduce the incidence of
this cancer in the future.
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